Evolent Health stock reports 46.90 percent Q2 revenue growth

Evolent Health (ISIN US30050B1017) reported USD 652.52 million in second-quarter 2026 revenue, a 46.90 percent year-over-year increase, according to StockTitan on August 6, 2026. The result gives Evolent Health stock a clear operating-growth story, but profitability remains the central counterweight.

Revenue growth meets a wider loss

For the three months ended June 30, 2026, Evolent recorded a net loss attributable to common shareholders of USD 28.36 million, while adjusted EBITDA was USD 28.05 million. The adjusted EBITDA margin was 4.30 percent, down from 8.50 percent a year earlier, according to StockTitan.

The company raised its 2026 revenue guidance to USD 2.6 billion-USD 2.7 billion and tightened adjusted EBITDA guidance to USD 120 million-USD 135 million. The guidance range is higher than the USD 2.4 billion-USD 2.6 billion revenue outlook cited for the earlier 2026 plan, while the EBITDA range leaves investors focused on conversion of growth into profit.

Analysts keep targets above the market

MarketBeat reported on September 25, 2026, that JPMorgan raised its price objective from USD 5.00 to USD 6.00 and assigned an overweight rating on August 18, 2026. The same report cited a USD 5.96 consensus price target, alongside 11 buy, four hold and one sell ratings.

Operational expansion also remains part of the company story. MarketScreener reported on September 21, 2026, that TransPerfect selected Evolent for enterprise-wide telephonic interpretation services across its payer network.

Prior close stays at EUR 3.07

Lang & Schwarz showed a prior close of EUR 3.07 for September 29, 2026. Evolent Health has a USD 392.6 million market capitalization as of September 30, 2026, while its 52-week range was USD 2.10 to USD 8.59; the figures frame a small-cap healthcare technology stock balancing fast revenue expansion against continuing losses.

More news and analyses on Evolent Health stock